Oligonucleotide CDMO Market Overview
As per Econ Market Research analysis, the Global Oligonucleotide CDMO Market generated revenue of US$ 1.88 Billion in 2026 and is forecast to achieve US$ 12.11 Billion by 2035, at a CAGR of 23.0% during the study period 2026–2035. The base year considered is 2025.
The Oligonucleotide CDMO Market has become an important specialized segment of pharmaceutical outsourcing as drug developers shift nucleic-acid programs from discovery into regulated clinical and commercial manufacturing. CDMOs provide synthesis, purification, analytical development, impurity characterization, conjugation, process optimization, scale-up, and GMP supply for antisense oligonucleotides, siRNA, guide RNA, aptamers, and related synthetic nucleic-acid modalities. Manufacturing is technically demanding because nucleotide coupling efficiency, backbone chemistry, sequence length, purification strategy, and modified building blocks influence final product quality. By 2026, 24 nucleic-acid drugs had received approval from the FDA, EMA, or both, supporting increasing demand for experienced manufacturing partners capable of handling validated commercial processes.
The USA represents the most developed national demand center within the Oligonucleotide CDMO Market due to its concentration of nucleic-acid drug developers, biotechnology companies, clinical programs, regulatory expertise, and specialized manufacturing infrastructure. Colorado has become a strategic manufacturing cluster through Agilent Technologies' nucleic-acid operations, while other domestic providers support development, analytical services, drug substance, and drug-product activities. Agilent's Frederick operation has been designed for siRNA, antisense molecules, and CRISPR guide RNA production, strengthening domestic access to commercial-grade therapeutic oligonucleotides. The company's major Frederick expansion is expected to create 160 life-science positions, demonstrating the scale of specialized workforce development required to support the industry's manufacturing pipeline.
Europe remains a major technical base for oligonucleotide contract development and manufacturing, with Switzerland and Germany hosting several companies specializing in complex synthetic APIs. Bachem, Lonza, BioSpring, EUROAPI, PolyPeptide Group, and CordenPharma contribute process-development expertise, GMP infrastructure, analytical capabilities, and international regulatory experience. Switzerland has particular strength in peptide and oligonucleotide production, while Germany continues to add nucleic-acid synthesis and API infrastructure. Europe accounted for 33.0% of the global Oligonucleotide CDMO Market in the identified base period, supported by established quality systems, experienced scientific teams, multinational pharmaceutical customers, and investment in large-scale manufacturing.
Oligonucleotide CDMO Market Latest Trends
One of the most important Oligonucleotide CDMO Market trends is the transition from isolated synthesis contracts toward integrated development-to-commercial platforms. Sponsors increasingly prefer partners that can manage process development, custom monomers, analytical methods, drug-substance manufacturing, conjugation, formulation, sterile filling, packaging, and regulatory documentation. This structure reduces technology transfers between separate vendors and allows process knowledge generated during development to remain within the manufacturing network.
Commercialization of RNA-targeted therapeutics is also changing capacity requirements. Early oligonucleotide programs often require gram-scale material, while therapies for larger patient populations can require substantially greater API quantities and predictable long-term production slots. CDMOs are therefore investing in larger synthesis equipment, scalable chromatography, alternative purification processes, solvent recovery systems, automation, and continuous process monitoring.
Integration of advanced conjugation technologies is another significant trend. GalNAc conjugation has increased the importance of expertise in chemically modified siRNA programs, while antibody-oligonucleotide conjugates and lipid-based delivery systems are creating interfaces between synthetic chemistry and advanced bioconjugation. CDMOs capable of handling these interfaces can support increasingly complex therapeutic architectures.
Digitalization is also influencing development workflows. Automated synthesis, electronic batch records, advanced analytical data processing, process modeling, and high-throughput sequence production are being introduced to reduce manual intervention and improve reproducibility. WuXi TIDES states that its platform includes 1,600 scientists supporting discovery, development, and manufacturing across its network, illustrating the scale of integrated scientific resources being deployed in this field.
Oligonucleotide CDMO Market Dynamics
The Oligonucleotide CDMO Market is influenced by the growing clinical maturity of RNA-targeted medicines, manufacturing complexity, regulatory requirements, and the availability of specialized production capacity. Drug developers frequently lack dedicated equipment for phosphoramidite chemistry, high-resolution purification, modified nucleotides, conjugation, and specialized analytical characterization. Outsourcing allows sponsors to access established GMP systems without building dedicated plants for each emerging modality. Competitive differentiation increasingly depends on process yield, impurity control, batch reproducibility, regulatory history, technology-transfer capability, and available commercial slots. North America held 39.55% market share in the identified period, illustrating the concentration of development programs and qualified manufacturing infrastructure in the region.
Drivers of Market Growth
Expanding clinical and commercial pipeline of oligonucleotide therapeutics.
The primary driver of the Oligonucleotide CDMO Market is the increasing number of antisense, siRNA, guide-RNA, and other nucleic-acid programs progressing toward regulated manufacturing. Sponsors moving from discovery into clinical development require GMP material, validated analytical procedures, controlled impurity profiles, stability programs, and documented raw-material systems. Commercial preparation places additional pressure on manufacturers because supply reliability becomes critical once patient treatment depends on continuous production.
Oligonucleotide therapeutics also address disease targets that may be difficult to modulate using conventional small molecules or proteins. This creates sustained interest across rare genetic diseases, neurological conditions, cardiometabolic disorders, liver diseases, and other therapeutic fields. Industry research identified 14 approved ASO drugs within a broader group of approved nucleic-acid medicines, demonstrating the established regulatory pathway that supports manufacturing demand.
Market Restraints
High capital intensity and specialized manufacturing requirements.
Oligonucleotide production requires dedicated synthesis equipment, controlled raw materials, purification systems, analytical instrumentation, trained personnel, solvent-management infrastructure, and GMP-qualified facilities. These requirements create substantial barriers for smaller manufacturers seeking to enter commercial-scale production. Long oligonucleotide sequences and highly modified molecules can create additional purification difficulties because closely related impurities must be separated from the desired full-length product.
Process losses during sequential nucleotide addition also affect material efficiency. Sponsors expect CDMOs to demonstrate consistent coupling performance while controlling deletion sequences, protecting-group related impurities, residual solvents, and other process-associated contaminants. Scaling the same chemistry from development to commercial quantities requires careful engineering rather than simple equipment enlargement. A typical 20-mer ASO requires at least 20 sequential coupling cycles, illustrating how repeated synthesis steps can amplify process-control requirements.
Market Opportunities
Expansion of integrated end-to-end services for advanced RNA medicines.
An important opportunity exists for CDMOs that connect oligonucleotide drug substance production with conjugation, formulation, analytical testing, sterile drug-product manufacturing, and regulatory support. Sponsors increasingly seek fewer external handoffs because each transfer introduces documentation requirements, analytical bridging, scheduling risk, and supply-chain complexity. Providers capable of linking early process development directly to commercial manufacturing can capture programs for longer periods.
The emergence of GalNAc-siRNA, guide RNA, PMO, aptamer, and antibody-oligonucleotide programs is also broadening the addressable manufacturing base. Specialized building blocks and advanced conjugation methods can create differentiated service offerings for manufacturers with proprietary chemistry expertise. WuXi TIDES disclosed support for 69 API and drug-product molecules through its TIDES platform during the referenced reporting period, indicating the expanding breadth of outsourced complex-modality programs.
Market Challenges
Maintaining purity and process consistency as oligonucleotide complexity increases.
The principal technical challenge is producing complex oligonucleotides at consistent quality when sequence structure, chemical modifications, conjugates, and delivery components vary substantially between programs. Impurities can be structurally similar to the target molecule, requiring advanced chromatographic methods, mass spectrometry, sequence-confirmation tools, and orthogonal analytical techniques. Process development must also anticipate how synthesis and purification performance changes when scale increases.
Commercial projects require validated methods, robust change control, documented raw-material traceability, and predictable release testing. Capacity expansion can create execution risk when equipment is commissioned faster than experienced scientific and quality personnel can be developed. WuXi's Changzhou oligonucleotide operation reports roughly 30 manufacturing lines at different scales, demonstrating the operational complexity that large multiproduct sites must coordinate while maintaining product segregation and GMP controls.
Oligonucleotide CDMO SWOT Analysis
Strengths
Specialized CDMOs possess established knowledge in phosphoramidite chemistry, purification, analytical characterization, conjugation, and modified nucleic-acid manufacturing.
Integrated service models allow sponsors to retain process knowledge from development through clinical manufacturing and commercial supply.
Experienced providers maintain regulatory quality systems that reduce the infrastructure burden placed on smaller biotechnology companies.
Oligonucleotide manufacturing combines specialized chemistry with high technical entry barriers, supporting long-term relationships between sponsors and qualified production partners.
Weaknesses
Production remains dependent on specialized raw materials, modified amidites, resins, purification media, solvents, and trained scientific personnel.
Manufacturing processes can create significant solvent use and waste streams, increasing environmental-management and process-efficiency requirements.
Technology transfer between different CDMO platforms can require redevelopment when equipment configuration or analytical methodology differs.
Capacity is concentrated among specialist providers, making customer programs sensitive to manufacturing-slot availability and project prioritization.
Opportunities
Commercialization of new RNA-targeted medicines creates opportunities for large-scale GMP manufacturing and long-term supply agreements.
GalNAc conjugation, guide-RNA manufacturing, PMO chemistry, aptamers, and antibody-oligonucleotide conjugates expand the service portfolio available to advanced CDMOs.
Sponsors increasingly value integrated API-to-drug-product offerings that reduce external transfers and simplify accountability.
Manufacturing investments in Asia-Pacific can provide additional global supply options and improve geographic diversification for multinational drug developers.
Threats
Rapid capacity construction could create competitive pressure if new facilities become operational faster than commercial demand develops.
Regulatory observations at multiproduct sites can affect customer confidence and delay supply programs.
Geopolitical restrictions may influence sourcing decisions for globally distributed pharmaceutical manufacturing networks.
New enzymatic synthesis technologies could alter the competitive position of conventional solid-phase manufacturers if they deliver improved scalability or material efficiency.
Oligonucleotide CDMO Segmentation Analysis
The Oligonucleotide CDMO Market is segmented according to service, oligonucleotide type, application, and end use. These categories reflect differences in technical requirements, regulatory maturity, manufacturing scale, analytical complexity, and customer purchasing behavior. Contract manufacturing typically serves clinical and commercial programs, while development services focus on process definition, optimization, method development, and technology transfer. Therapeutic projects require particularly stringent quality systems, while research and diagnostic projects may use different specifications and batch structures.
By Service
Contract Development includes process design, scale-up strategy, analytical method development, purification optimization, impurity characterization, stability support, and preparation for GMP transfer. These activities are important because early manufacturing decisions can determine whether a molecule can be produced efficiently at clinical and commercial scales. Development teams also help sponsors define specifications and identify process parameters that influence product quality.
Contract Manufacturing covers GMP synthesis, purification, isolation, analytical release, documentation, and supply of clinical or commercial material. It maintains the leading position because sponsors with advanced pipelines require qualified infrastructure and reliable batch execution rather than laboratory-scale synthesis alone. Contract manufacturing represented 51.68% of the market in a recent segmentation assessment.
By Type
Antisense Oligonucleotides form the established type segment because ASO technology has produced multiple approved therapies and a substantial clinical pipeline. These molecules require expertise in backbone modifications, sequence-dependent purification, impurity profiling, and controlled synthesis processes. CDMOs supporting ASO programs may manage projects ranging from early toxicology material through validated commercial API supply.
Small Interfering RNA represents another major category, particularly as liver-targeted delivery technologies support broader therapeutic development. Manufacturing can include passenger and guide strands, annealing operations, conjugation, purification, and characterization of duplex products. Other oligonucleotides include guide RNA, aptamers, PMOs, and emerging synthetic nucleic-acid structures. ASOs accounted for 58.23% of the identified market segmentation, reflecting their established development and manufacturing base.
By Application
Therapeutic applications represent the largest application category because clinical oligonucleotide medicines require highly controlled drug-substance production and comprehensive regulatory documentation. CDMOs serving therapeutic programs provide process development, GMP manufacturing, analytical validation, stability work, quality support, and commercialization preparation. These requirements create deeper service relationships than standard research synthesis.
Research applications involve discovery libraries, screening sequences, preclinical candidate generation, and custom modified oligonucleotides. Diagnostic applications use synthetic nucleic acids in assays, molecular detection technologies, reference materials, and specialized testing platforms. Manufacturing requirements can differ according to intended use, purity specifications, quantity, and regulatory classification. Therapeutic applications represented 56.74% of the identified market, supported by expanding clinical pipelines and commercialization activity.
By End Use
Pharmaceutical and biopharmaceutical companies are the principal customers for oligonucleotide CDMO services because they manage therapeutic pipelines requiring development, clinical supply, regulatory submissions, validation, and commercial production. Large companies may outsource selected process stages despite maintaining internal capabilities, while biotechnology companies frequently use CDMOs as their primary manufacturing infrastructure.
Diagnostic companies purchase oligonucleotides for molecular testing platforms and related products, where batch consistency and sequence accuracy are important performance requirements. Other end users include research organizations and specialized advanced-therapy developers requiring custom nucleic-acid materials. Outsourcing decisions are typically influenced by technical expertise, available capacity, regulatory history, delivery schedules, and molecule complexity. Pharmaceutical and biotechnology organizations represented 52.71% of demand in the cited market segmentation.
Regional Analysis
Regional performance in the Oligonucleotide CDMO Market reflects differences in biotechnology pipelines, pharmaceutical manufacturing infrastructure, regulatory expertise, skilled labor availability, capital investment, and proximity to major drug developers. North America remains a major development and manufacturing hub, while Europe maintains strong specialist API capabilities. Asia-Pacific is adding capacity through China, South Korea, Japan, and India, creating additional sourcing options for global sponsors. The regional structure continues to evolve as pharmaceutical companies seek manufacturing resilience and multi-site supply strategies.
North America: North America combines a dense biotechnology ecosystem with established pharmaceutical development infrastructure and significant experience managing FDA-regulated manufacturing programs. The United States hosts major developers of antisense and siRNA medicines and specialized CDMO operations capable of supporting development and commercial-scale supply. Agilent maintains nucleic-acid manufacturing activities in Colorado, while Thermo Fisher and other providers contribute broader contract development and manufacturing infrastructure.
Investment in domestic production is strengthening the region's position in strategic nucleic-acid manufacturing. Sponsors frequently value proximity between development teams and manufacturing sites during process transfer, analytical troubleshooting, regulatory inspection preparation, and launch planning. North American providers are also expanding integrated models that combine oligonucleotide services with complementary advanced-therapy capabilities.
Canada contributes additional biomanufacturing infrastructure and became more closely integrated with Agilent's advanced-therapeutics strategy following the combination of BIOVECTRA capabilities with the company's U.S. nucleic-acid operations. North America accounted for 39.55% of the identified global market, reflecting its concentration of clinical pipelines, manufacturing assets, and regulatory experience.
Europe: Europe has a strong position in specialty chemical manufacturing, pharmaceutical APIs, advanced therapeutics, peptides, and oligonucleotide processing. Switzerland hosts Bachem, Lonza, and PolyPeptide Group, while Germany supports specialized nucleic-acid manufacturing through companies including BioSpring and other pharmaceutical-service providers. This supplier base gives European sponsors access to development laboratories, GMP synthesis, purification expertise, analytical services, and commercial production infrastructure.
European CDMOs are increasing investment in facilities designed for larger-volume synthetic APIs. Bachem's Bubendorf site combines oligonucleotide synthesis technologies with process development, analytics, supply-chain operations, and regulatory support. Lonza is extending advanced-synthesis capabilities into antibody-oligonucleotide and other bioconjugate platforms, reflecting convergence between oligonucleotide chemistry and targeted delivery technologies.
Customers also benefit from manufacturers accustomed to EMA requirements and international regulatory submissions. Europe's share stood at 33.0% in the referenced market assessment, confirming its importance as a global technical and manufacturing hub rather than simply a regional supply base.
Asia-Pacific: Asia-Pacific is becoming increasingly important as manufacturers in China, South Korea, Japan, and India expand complex pharmaceutical development and production capabilities. WuXi AppTec provides oligonucleotide, peptide, conjugate, analytical, and drug-product services through its TIDES platform, while ST Pharm has developed substantial experience in oligonucleotide APIs. Japanese companies such as Ajinomoto and Kaneka add specialized synthesis capabilities, and Indian CDMOs are building participation in advanced modalities.
Regional manufacturers can compete through integrated service models, expanding scientific workforces, modern manufacturing campuses, and established relationships with global biotechnology customers. Asian providers are also investing in process development, custom building blocks, conjugation, and commercial manufacturing rather than competing solely on routine synthesis.
The region's role is increasingly connected to global supply diversification as sponsors consider multiple manufacturing locations for strategic products. Asia-Pacific held 22.7% of the identified global market, with contract manufacturing forming the leading regional service category.
Middle East & Africa: The Middle East & Africa Oligonucleotide CDMO Market remains at an earlier stage than North America, Europe, and Asia-Pacific. Local demand is linked to expanding biotechnology investment, genomics programs, precision-medicine initiatives, clinical research, and national pharmaceutical-manufacturing strategies. However, commercial-scale oligonucleotide synthesis and purification infrastructure remains concentrated outside the region, resulting in significant reliance on international CDMO networks.
Gulf countries are investing in pharmaceutical localization and advanced life-science ecosystems, which may eventually support regional nucleic-acid development and manufacturing partnerships. South Africa also contributes academic, diagnostic, and pharmaceutical capabilities, although specialized therapeutic oligonucleotide production remains limited.
Future opportunities are likely to center on technology partnerships, analytical laboratories, clinical supply, fill-finish capabilities, and regional distribution before fully integrated API manufacturing becomes widespread. One industry assessment places the Middle East & Africa share at 2.03%, illustrating the present difference between regional demand potential and established specialist manufacturing capacity.
Competitive Landscape
Competition in the Oligonucleotide CDMO Market is based on synthesis scale, technical chemistry, purification performance, analytical depth, regulatory history, commercial capacity, project execution, and ability to manage complex modifications. Major companies are investing in facilities and technologies that support projects from preclinical development through commercial supply. The market includes specialist oligonucleotide manufacturers, integrated pharmaceutical CDMOs, global CRDMOs, and companies extending peptide or advanced-synthesis expertise into nucleic-acid manufacturing.
Agilent Technologies competes through dedicated nucleic-acid manufacturing and analytical capabilities, while Bachem combines specialist synthetic API expertise with expanding industrial-scale production. WuXi AppTec differentiates through an integrated discovery-to-commercial TIDES platform. ST Pharm, Thermo Fisher Scientific, Lonza, Ajinomoto, BioSpring, PolyPeptide Group, and CordenPharma strengthen competition through specialized chemistry, international site networks, and complementary advanced-modality services.
Commercial customers increasingly assess providers on supply continuity and future capacity rather than short-term production price alone. Large late-stage programs may require reserved manufacturing slots, validated scale-up, redundant raw-material sourcing, and long-term quality commitments. The five identified leading companies collectively represented 50% of the market in the referenced competitive assessment, demonstrating meaningful concentration while leaving substantial opportunity for specialist and emerging suppliers.
List of Top Oligonucleotide CDMO Companies
Agilent Technologies (U.S.)
Bachem (Switzerland)
WuXi AppTec (China)
Thermo Fisher Scientific (U.S.)
ST Pharm (South Korea)
Lonza (Switzerland)
Eurofins Scientific (Luxembourg)
Ajinomoto (Japan)
EUROAPI (France)
PolyPeptide Group (Switzerland)
BioSpring (Germany)
Aurigene Pharmaceutical Services (India)
Kaneka Corporation (Japan)
Syngene International (India)
CordenPharma (Luxembourg)
Leading Companies by Market Share
Agilent Technologies: Agilent is identified as the market leader based on its dedicated nucleic-acid solutions operations, GMP oligonucleotide API experience, U.S. manufacturing footprint, analytical capabilities, and continuing expansion of therapeutic nucleic-acid capacity. Its estimated global Oligonucleotide CDMO Market share is 12%, placing it at the leading position in the referenced competitive assessment.
Ajinomoto: Ajinomoto participates through specialized oligonucleotide and PMO manufacturing capabilities, including liquid-phase technologies and integrated development services. An industry competitive dataset places its share at 20% within the oligonucleotide-focused supplier grouping used in that analysis, although market-share methodologies differ substantially among industry assessments and therefore should not be treated as directly interchangeable with broader global CDMO estimates.
Investment Trends & Opportunities
Investment in the Oligonucleotide CDMO Market is increasingly directed toward commercial-scale capacity rather than laboratory synthesis alone. New projects focus on larger manufacturing trains, downstream purification, solvent handling, lyophilization, analytical laboratories, digital control systems, conjugation capabilities, and GMP infrastructure. This reflects a change in customer requirements as therapeutic programs advance from small clinical batches toward repeat commercial supply.
Investors are also prioritizing integrated platforms that can capture a greater portion of each development program. A CDMO that provides early process development, building-block sourcing, API manufacturing, analytical validation, conjugation, drug-product support, and regulatory documentation can maintain customer relationships through multiple clinical stages. Such platforms can reduce handoffs and improve manufacturing continuity.
Europe and North America continue to receive major capacity investments, while Asia-Pacific suppliers are expanding both production scale and technical scope. Opportunities also exist in technologies designed to reduce solvent use, improve coupling efficiency, increase purification yield, and support longer or chemically complex sequences.
Bachem invested CHF 332.6 million during its referenced investment period, including work associated with its large-scale production program and site-network development. This commitment illustrates how leading suppliers are using capital expansion to prepare for commercial-scale peptide and oligonucleotide demand.
Product Innovation & Development
Innovation in the Oligonucleotide CDMO Market increasingly focuses on manufacturing technologies rather than synthesis capacity alone. Traditional solid-phase synthesis remains widely used, but manufacturers are developing complementary liquid-phase, enzymatic, ligation-based, and hybrid approaches that may improve scalability or reduce material consumption for selected sequences. Process development also targets higher coupling efficiency, improved impurity separation, solvent reduction, and more efficient downstream recovery.
Modified oligonucleotides are creating additional innovation requirements. GalNAc conjugates, PMOs, guide RNAs, lipid-modified sequences, PEGylated products, and antibody-oligonucleotide conjugates require different building blocks and analytical strategies. CDMOs are therefore broadening internal chemistry libraries and adding conjugation expertise to support these architectures.
Analytical development is becoming equally important. High-resolution mass spectrometry, chromatographic separation, sequence confirmation, impurity mapping, and automated data interpretation can shorten development timelines and strengthen batch release control. Manufacturers are also applying digital tools to manufacturing records, process monitoring, deviation analysis, and scale-up.
WuXi's discovery platform reports capability to produce 45,900 oligonucleotides annually, demonstrating how high-throughput synthesis and automated workflow design are expanding alongside commercial manufacturing technologies.
Recent Developments (2023–2026)
In April 2026, Bachem inaugurated Building K at its Bubendorf manufacturing campus to expand industrial-scale production capabilities for modern peptide and oligonucleotide active ingredients.
In March 2026, Agilent Technologies launched Agilent Advanced Therapeutics by integrating its Canadian BIOVECTRA capabilities with its U.S. nucleic-acid manufacturing operations into a unified CDMO platform.
In February 2026, Lonza expanded its Advanced Synthesis activities in Oss to support emerging bioconjugates including antibody-oligonucleotide conjugates and related targeted-delivery technologies.
In October 2025, Ajinomoto Bio-Pharma Services entered a collaboration with Gene Tools to connect early-stage PMO synthesis with purification, quality control, and subsequent regulated manufacturing support.
In October 2025, Bachem announced progress in commissioning its Bubendorf expansion while securing adjacent property in California to support future production-capacity development in the United States.
In April 2025, WuXi AppTec reported that its Changzhou and Taixing API manufacturing operations had successfully completed U.S. regulatory inspections, reinforcing its international manufacturing and quality positioning.
Scope of the Oligonucleotide CDMO Market Report
The Oligonucleotide CDMO Market report covers outsourced development and manufacturing activities associated with synthetic oligonucleotide drug substances and related advanced nucleic-acid modalities. The scope includes contract development and contract manufacturing services and assesses how pharmaceutical, biotechnology, diagnostic, and specialized research customers use external manufacturing partners throughout the product lifecycle.
The report evaluates the market by oligonucleotide type, including antisense oligonucleotides, small interfering RNA, and other oligonucleotide formats. Application coverage includes therapeutic, research, and diagnostic uses, allowing assessment of differences in quality requirements, manufacturing scale, analytical testing, and commercial maturity. End-use analysis examines pharmaceutical and biopharmaceutical companies, diagnostic companies, and other specialist customers.
Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa, with analysis of manufacturing infrastructure, supplier positioning, capacity additions, regulatory expertise, and customer demand. Competitive coverage evaluates leading organizations through their production capabilities, geographic footprint, technology platforms, integrated service offerings, facility investments, partnerships, and recent strategic actions.
The report also examines manufacturing trends such as advanced conjugation, GMP scale-up, automation, high-throughput synthesis, alternative synthesis technologies, process intensification, purification improvements, and API-to-drug-product integration. The competitive universe contains at least 15 established companies spanning specialized oligonucleotide manufacturers and diversified global CDMO organizations, providing a broad assessment of the suppliers shaping outsourced nucleic-acid development and manufacturing.
Oligonucleotide CDMO Market Segmentation
| Segment Category | Segment Values |
|---|---|
| Service |
|
| Type |
|
| Application |
|
| End Use |
|
Key Players
- Agilent Technologies (U.S.)
- Bachem (Switzerland)
- WuXi AppTec (China)
- Thermo Fisher Scientific (U.S.)
- ST Pharm (South Korea)
- Lonza (Switzerland)
- Eurofins Scientific (Luxembourg)
- Ajinomoto (Japan)
- EUROAPI (France)
- PolyPeptide Group (Switzerland)
- BioSpring (Germany)
- Aurigene Pharmaceutical Services (India)
- Kaneka Corporation (Japan)
- Syngene International (India)
- and CordenPharma (Luxembourg)
Table of Contents
1. GLOBAL OLIGONUCLEOTIDE CDMO MARKET–REPORT OVERVIEW
- 1.1. SCOPE OF THE REPORT
- 1.2. MARKET SEGMENT ANALYSIS
- 1.3. REGULATORY SCENARIO BY REGION/COUNTRY
- 1.4. MARKET INVESTMENT SCENARIO STRATEGIC
- 1.5. MARKET ANALYSIS BY BY SERVICE (USD MILLION)
- 1.5.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY BY SERVICE (2026-2035)
- 1.5.2 CONTRACT DEVELOPMENT
- 1.5.3 CONTRACT MANUFACTURING
- 1.6. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY BY SERVICE IN 2026 & 2035
- 1.7. MARKET ANALYSIS BY BY TYPE (USD MILLION)
- 1.7.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY BY TYPE (2026-2035)
- 1.7.2 ANTISENSE OLIGONUCLEOTIDES
- 1.7.3 SMALL INTERFERING RNA
- 1.7.4 OTHER OLIGONUCLEOTIDES
- 1.8. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY BY TYPE IN 2026 & 2035
- 1.9. MARKET ANALYSIS BY BY APPLICATION (USD MILLION)
- 1.9.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY BY APPLICATION (2026-2035)
- 1.9.2 THERAPEUTIC
- 1.9.3 RESEARCH
- 1.9.4 DIAGNOSTIC
- 1.10. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY BY APPLICATION IN 2026 & 2035
- 1.11. MARKET ANALYSIS BY BY END USE (USD MILLION)
- 1.11.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY BY END USE (2026-2035)
- 1.11.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
- 1.11.3 DIAGNOSTIC COMPANIES
- 1.11.4 OTHERS
- 1.12. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY BY END USE IN 2026 & 2035
2. DRIVER RESTRAINT CHALLENGE AND OPPORTUNITIES OF OLIGONUCLEOTIDE CDMO MARKET
- 2.1. DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
- 2.1.1 MARKET DRIVER ANALYSIS
- 2.1.2 MARKET RESTRAINT ANALYSIS
- 2.1.3 MARKET OPPORTUNITY
- 2.2. MARKET CHALLENGES
3. GLOBAL GROWTH TRENDS
- 3.1. INDUSTRY TRENDS
- 3.1.1 SWOT ANALYSIS
- 3.1.1.1 Strengths
- 3.1.1.2 Weaknesses
- 3.1.1.3 Opportunities
- 3.1.1.4 Threats
- 3.1.2 PESTEL ANALYSIS
- 3.1.2.1 Political Landscape
- 3.1.2.2 Economic Landscape
- 3.1.2.3 Social Landscape
- 3.1.2.4 Technological Landscape
- 3.1.2.5 Environmental Landscape
- 3.1.2.6 Legal Landscape
- 3.1.3 PORTER'S FIVE FORCES ANALYSIS
- 3.1.3.1 Bargaining Power of Suppliers
- 3.1.3.2 Bargaining Power of Buyers
- 3.1.3.3 Threat of Substitute
- 3.1.3.4 Threat of New Entrant
- 3.1.3.5 Competitive Rivalry
- 3.1.1 SWOT ANALYSIS
- 3.2. POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4. POST COVID ANALYSIS
- 4.1. COVID V ANALYSIS
- 4.2. COVID U ANALYSIS
- 4.3. COVID L ANALYSIS
- 4.4. COVID W ANALYSIS
5. COMPANIES ANALYSIS
- 5.1. PLAYERS COVERED: RANKING BY OLIGONUCLEOTIDE CDMO MARKET REVENUE
- 5.2. TOP COMPANIES MARKET SHARE (%)
6. EXECUTIVE SUMMARY
7. GLOBAL OLIGONUCLEOTIDE CDMO MARKET FORECAST, 2022-2035, (USD MILLION)
- 7.1. GLOBAL OLIGONUCLEOTIDE CDMO MARKET REVENUE AND MARKET SHARE BY REGIONS
- 7.2. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY REGION (2022-2029)
- 7.3. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY REGION (2030-2035)
- 7.3.1.1 North America
- 7.3.1.2 Europe
- 7.3.1.3 Asia Pacific
- 7.3.1.4 Latin America
- 7.3.1.5 Middle East & Africa
8. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 8.1. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 8.2. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 8.3. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 8.3.1.1 United States
- 8.3.1.2 Canada
- 8.3.1.3 Mexico
9. EUROPE OLIGONUCLEOTIDE CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 9.1. EUROPE OLIGONUCLEOTIDE CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 9.2. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 9.3. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 9.3.1.1 United Kingdom
- 9.3.1.2 Germany
- 9.3.1.3 France
- 9.3.1.4 Spain
- 9.3.1.5 Italy
- 9.3.1.6 Rest of Europe
10. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 10.1. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 10.2. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 10.3. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 10.3.1.1 China
- 10.3.1.2 India
- 10.3.1.3 Japan
- 10.3.1.4 Australia
- 10.3.1.5 South Korea
- 10.3.1.6 Rest of Asia Pacific
11. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 11.1. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 11.2. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 11.3. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 11.3.1.1 Saudi Arabia
- 11.3.1.2 South Africa
- 11.3.1.3 Rest of MEA
12. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 12.1. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 12.2. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 12.3. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 12.3.1.1 Brazil
- 12.3.1.2 Argentina
- 12.3.1.3 Rest of Latin America
13. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SEGMENT BY BY SERVICE, (USD MILLION)
- 13.1. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2022-2029)
- 13.2. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2030-2035)
- 13.3. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2022-2029)
- 13.4. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2030-2035)
- 13.5. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2022-2029)
- 13.6. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2030-2035)
- 13.7. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2022-2029)
- 13.8. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2030-2035)
- 13.9. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2022-2029)
- 13.10. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2030-2035)
- 13.11. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2022-2029)
- 13.12. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY SERVICE (2030-2035)
13. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SEGMENT BY BY TYPE, (USD MILLION)
- 13.13. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2022-2029)
- 13.14. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2030-2035)
- 13.15. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2022-2029)
- 13.16. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2030-2035)
- 13.17. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2022-2029)
- 13.18. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2030-2035)
- 13.19. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2022-2029)
- 13.20. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2030-2035)
- 13.21. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2022-2029)
- 13.22. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2030-2035)
- 13.23. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2022-2029)
- 13.24. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY TYPE (2030-2035)
13. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SEGMENT BY BY APPLICATION, (USD MILLION)
- 13.25. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.26. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.27. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.28. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.29. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.30. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.31. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.32. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.33. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.34. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.35. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.36. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
13. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SEGMENT BY BY END USE, (USD MILLION)
- 13.37. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2022-2029)
- 13.38. GLOBAL OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2030-2035)
- 13.39. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2022-2029)
- 13.40. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2030-2035)
- 13.41. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2022-2029)
- 13.42. EUROPE OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2030-2035)
- 13.43. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2022-2029)
- 13.44. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2030-2035)
- 13.45. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2022-2029)
- 13.46. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2030-2035)
- 13.47. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2022-2029)
- 13.48. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET AND MARKET SHARE BY BY END USE (2030-2035)
14. COMPANY PROFILES
- 14.1. AGILENT TECHNOLOGIES (U.S.)
- 14.1.1 COMPANY DETAIL
- 14.1.2 FINANCIALS (USD MILLIONS)
- 14.1.3 PRODUCT SUMMARY
- 14.1.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.2. BACHEM (SWITZERLAND)
- 14.2.1 COMPANY DETAIL
- 14.2.2 FINANCIALS (USD MILLIONS)
- 14.2.3 PRODUCT SUMMARY
- 14.2.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.3. WUXI APPTEC (CHINA)
- 14.3.1 COMPANY DETAIL
- 14.3.2 FINANCIALS (USD MILLIONS)
- 14.3.3 PRODUCT SUMMARY
- 14.3.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.4. THERMO FISHER SCIENTIFIC (U.S.)
- 14.4.1 COMPANY DETAIL
- 14.4.2 FINANCIALS (USD MILLIONS)
- 14.4.3 PRODUCT SUMMARY
- 14.4.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.5. ST PHARM (SOUTH KOREA)
- 14.5.1 COMPANY DETAIL
- 14.5.2 FINANCIALS (USD MILLIONS)
- 14.5.3 PRODUCT SUMMARY
- 14.5.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.6. LONZA (SWITZERLAND)
- 14.6.1 COMPANY DETAIL
- 14.6.2 FINANCIALS (USD MILLIONS)
- 14.6.3 PRODUCT SUMMARY
- 14.6.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.7. EUROFINS SCIENTIFIC (LUXEMBOURG)
- 14.7.1 COMPANY DETAIL
- 14.7.2 FINANCIALS (USD MILLIONS)
- 14.7.3 PRODUCT SUMMARY
- 14.7.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.8. AJINOMOTO (JAPAN)
- 14.8.1 COMPANY DETAIL
- 14.8.2 FINANCIALS (USD MILLIONS)
- 14.8.3 PRODUCT SUMMARY
- 14.8.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.9. EUROAPI (FRANCE)
- 14.9.1 COMPANY DETAIL
- 14.9.2 FINANCIALS (USD MILLIONS)
- 14.9.3 PRODUCT SUMMARY
- 14.9.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.10. POLYPEPTIDE GROUP (SWITZERLAND)
- 14.10.1 COMPANY DETAIL
- 14.10.2 FINANCIALS (USD MILLIONS)
- 14.10.3 PRODUCT SUMMARY
- 14.10.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.11. BIOSPRING (GERMANY)
- 14.11.1 COMPANY DETAIL
- 14.11.2 FINANCIALS (USD MILLIONS)
- 14.11.3 PRODUCT SUMMARY
- 14.11.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.12. AURIGENE PHARMACEUTICAL SERVICES (INDIA)
- 14.12.1 COMPANY DETAIL
- 14.12.2 FINANCIALS (USD MILLIONS)
- 14.12.3 PRODUCT SUMMARY
- 14.12.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.13. KANEKA CORPORATION (JAPAN)
- 14.13.1 COMPANY DETAIL
- 14.13.2 FINANCIALS (USD MILLIONS)
- 14.13.3 PRODUCT SUMMARY
- 14.13.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.14. SYNGENE INTERNATIONAL (INDIA)
- 14.14.1 COMPANY DETAIL
- 14.14.2 FINANCIALS (USD MILLIONS)
- 14.14.3 PRODUCT SUMMARY
- 14.14.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.15. CORDENPHARMA (LUXEMBOURG)
- 14.15.1 COMPANY DETAIL
- 14.15.2 FINANCIALS (USD MILLIONS)
- 14.15.3 PRODUCT SUMMARY
- 14.15.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
15. CONCLUSION
16. REFERENCE LINK
17. APPENDIX
- 17.1. METHODOLOGY
- 17.2. RESEARCH DATA SOURCE
- 17.2.1 SECONDARY DATA
- 17.2.2 KEY DATA FROM SECONDARY
- 17.2.3 PRIMARY DATA
- 17.2.4 KEY DATA FROM PRIMARY
- 17.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
- 17.2.6 MARKET ESTIMATION
- 17.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
- 17.2.8 LEGAL DISCLAIMER
18. RESEARCH SCOPE
LIST OF TABLES
- TABLE 1. MARKET SEGMENT
- TABLE 2. GLOBAL OLIGONUCLEOTIDE CDMO MARKET GROWTH RATE BY BY SERVICE (2026-2035)
- TABLE 3. GLOBAL OLIGONUCLEOTIDE CDMO MARKET GROWTH RATE BY BY TYPE (2026-2035)
- TABLE 4. GLOBAL OLIGONUCLEOTIDE CDMO MARKET GROWTH RATE BY BY APPLICATION (2026-2035)
- TABLE 5. GLOBAL OLIGONUCLEOTIDE CDMO MARKET GROWTH RATE BY BY END USE (2026-2035)
- TABLE 6. COMPANY'S RANK BY OLIGONUCLEOTIDE CDMO MARKET REVENUE
- TABLE 7. GLOBAL OLIGONUCLEOTIDE CDMO MARKET — MARKET SNAPSHOT & KEY BUYING CRITERIA, 2026–2035
- TABLE 8. GLOBAL OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 9. GLOBAL OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 10. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY REGION, USD MILLION (2022-2029)
- TABLE 11. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY REGION, (2022-2029)
- TABLE 12. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY REGION, USD MILLION (2030-2035)
- TABLE 13. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE BY REGION, (2030-2035)
- TABLE 14. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 15. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 16. EUROPE OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 17. EUROPE OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 18. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 19. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 20. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 21. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 22. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 23. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 24. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 25. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 26. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 27. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 28. UNITED STATES OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 29. UNITED STATES OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 30. CANADA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 31. CANADA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 32. MEXICO OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 33. MEXICO OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 34. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 35. EUROPE OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 36. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 37. EUROPE OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 38. UNITED KINGDOM OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 39. UNITED KINGDOM OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 40. GERMANY OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 41. GERMANY OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 42. FRANCE OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 43. FRANCE OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 44. SPAIN OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 45. SPAIN OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 46. ITALY OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 47. ITALY OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 48. REST OF EUROPE OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 49. REST OF EUROPE OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 50. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 51. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 52. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 53. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 54. CHINA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 55. CHINA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 56. INDIA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 57. INDIA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 58. JAPAN OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 59. JAPAN OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 60. AUSTRALIA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 61. AUSTRALIA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 62. SOUTH KOREA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 63. SOUTH KOREA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 64. REST OF ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 65. REST OF ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 66. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 67. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 68. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 69. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 70. SAUDI ARABIA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 71. SAUDI ARABIA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 72. SOUTH AFRICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 73. SOUTH AFRICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 74. REST OF MEA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 75. REST OF MEA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 76. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 77. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 78. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 79. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 80. BRAZIL OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 81. BRAZIL OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 82. ARGENTINA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 83. ARGENTINA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 84. REST OF LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 85. REST OF LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 86. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2022-2029)
- TABLE 87. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2030-2035)
- TABLE 88. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2022-2029)
- TABLE 89. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2030-2035)
- TABLE 90. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2022-2029)
- TABLE 91. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2030-2035)
- TABLE 92. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2022-2029)
- TABLE 93. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2030-2035)
- TABLE 94. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2022-2029)
- TABLE 95. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2030-2035)
- TABLE 96. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2022-2029)
- TABLE 97. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY SERVICE, USD MILLION (2030-2035)
- TABLE 98. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2022-2029)
- TABLE 99. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2030-2035)
- TABLE 100. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2022-2029)
- TABLE 101. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2030-2035)
- TABLE 102. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2022-2029)
- TABLE 103. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2030-2035)
- TABLE 104. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2022-2029)
- TABLE 105. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2030-2035)
- TABLE 106. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2022-2029)
- TABLE 107. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2030-2035)
- TABLE 108. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2022-2029)
- TABLE 109. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY TYPE, USD MILLION (2030-2035)
- TABLE 110. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 111. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 112. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 113. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 114. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 115. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 116. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 117. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 118. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 119. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 120. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 121. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 122. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2022-2029)
- TABLE 123. GLOBAL OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2030-2035)
- TABLE 124. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2022-2029)
- TABLE 125. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2030-2035)
- TABLE 126. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2022-2029)
- TABLE 127. EUROPE OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2030-2035)
- TABLE 128. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2022-2029)
- TABLE 129. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2030-2035)
- TABLE 130. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2022-2029)
- TABLE 131. MIDDLE EAST & AFRICA OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2030-2035)
- TABLE 132. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2022-2029)
- TABLE 133. SOUTH AMERICA OLIGONUCLEOTIDE CDMO MARKET BY BY END USE, USD MILLION (2030-2035)
LIST OF FIGURES
- FIGURE 1. MARKET OVERVIEW
- FIGURE 2. REGIONAL SHARE
- FIGURE 3. MARKET REVENUE (USD MILLION)
- FIGURE 4. DROC OF OLIGONUCLEOTIDE CDMO MARKET ANALYSIS
- FIGURE 5. SWOT ANALYSIS
- FIGURE 6. PESTEL ANALYSIS
- FIGURE 7. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 8. COVID V, U, W AND L ANALYSIS
- FIGURE 9. LEADING COMPANIES
- FIGURE 10. REGIONAL ANALYSIS
- FIGURE 11. COUNTRY ANALYSIS
- FIGURE 12. GLOBAL OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 13. GLOBAL OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 14. GLOBAL OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION), BY REGION
- FIGURE 15. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE, (2026), BY REGION
- FIGURE 16. GLOBAL OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION), BY REGION
- FIGURE 17. GLOBAL OLIGONUCLEOTIDE CDMO MARKET SHARE, (2035), BY REGION
- FIGURE 18. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 19. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 20. EUROPE OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 21. EUROPE OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 22. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 23. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 24. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 25. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 26. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 27. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 28. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 29. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 30. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 31. NORTH AMERICA OLIGONUCLEOTIDE CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 32. UNITED STATES OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 33. UNITED STATES OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 34. CANADA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 35. CANADA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 36. MEXICO OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 37. MEXICO OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 38. EUROPE OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 39. EUROPE OLIGONUCLEOTIDE CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 40. EUROPE OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 41. EUROPE OLIGONUCLEOTIDE CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 42. UNITED KINGDOM OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 43. UNITED KINGDOM OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 44. GERMANY OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 45. GERMANY OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 46. FRANCE OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 47. FRANCE OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 48. SPAIN OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 49. SPAIN OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 50. ITALY OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 51. ITALY OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 52. REST OF EUROPE OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 53. REST OF EUROPE OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 54. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 55. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 56. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 57. ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 58. CHINA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 59. CHINA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 60. INDIA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 61. INDIA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 62. JAPAN OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 63. JAPAN OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 64. AUSTRALIA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 65. AUSTRALIA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 66. SOUTH KOREA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 67. SOUTH KOREA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 68. REST OF ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 69. REST OF ASIA PACIFIC OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 70. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 71. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 72. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 73. MIDDLE EAST AND AFRICA OLIGONUCLEOTIDE CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 74. SAUDI ARABIA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 75. SAUDI ARABIA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 76. SOUTH AFRICA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 77. SOUTH AFRICA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 78. REST OF MEA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 79. REST OF MEA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 80. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 81. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 82. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 83. LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 84. BRAZIL OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 85. BRAZIL OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 86. ARGENTINA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 87. ARGENTINA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 88. REST OF LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 89. REST OF LATIN AMERICA OLIGONUCLEOTIDE CDMO MARKET, (2030-2035), (USD MILLION)
Research Methodology
Our research methodology is carefully designed to deliver the clients with the most accurate, relevant, and actionable market insights to enable clear decision-making and leveraging of opportunities in the markets. We believe consistency, depth in analysis, and a tailored approach in each report are what help set us apart in the industry. The research methodology is based on an integrating research process consisting of in-depth data collection, a complex analysis, and a stringent validation system.
Data Collection
Data collection forms the basis of our study and gathers diverse authentic data to build the basis for deeper study in terms of market trends, competitive landscape, and growth prospects. Data collection takes place through two channels of main activities as follows:
Primary Data Collection
Primary data collection allows collecting real-time and firsthand information from market participants. This is an engagement process conducted by our team with other industry stakeholders, where a much deeper insight than any published data is pursued. This process includes:
- Direct Interviews – We interview the key decision-makers such as CEOs, product managers, innovation heads, and marketing directors to gather both qualitative and quantitative information. The questionnaire covers emerging trends, customer preferences, regulatory impact, and competitors’ strategies.
- Demand and Supply-Side Inputs – Interviews and surveys with supply and demand-side stakeholders provide a balanced view of prevailing market conditions, including feedback from manufacturers, distributors, suppliers, and end-users.
- Expert Opinions – Consultations with industry experts and domain specialists provide insights into future market direction, risks, and opportunities.
- Focus Groups and Online Surveys – Focus groups and surveys are used to understand consumer preferences and adoption probability of new products or services.
Primary research forms the core of our data validation process by offering direct insights into the market, addressing limitations in secondary data, and allowing for an adaptable research process.
Secondary Data Collection
Secondary research serves as a robust foundation for understanding market context, historical data, and larger trends. It involves systematic gathering of existing information from verified sources.
- Industry Reports and Publications – Market reports, white papers, and case studies from credible sources provide a broad view of the market landscape and key players.
- Government and Public Records – Data from government agencies and regulatory bodies helps analyze economic factors and policy impacts.
- News and Media Outlets – Monitoring news articles, press releases, and media reports keeps us updated on market developments and M&A activity.
- Proprietary and Paid Databases – Databases such as Bloomberg, Factiva, D&B Hoovers, and Thomson Reuters provide validated and cross-referenced data.
- Financial Reports and SEC Filings – Financial statements, annual reports, and investor presentations provide insights into revenue structures and profitability.
This combination of primary and secondary data sources enables us to provide a comprehensive view of the market, supported by authenticated information across multiple sources.
Data Analysis Techniques
With the data collected, we initiate a rigorous analysis phase. We analyze market dynamics, growth patterns, and future performance using analytical models and statistical tools.
Top-Down and Bottom-Up Market Sizing Approaches
- Top-Down Approach – Starts with global market size and distributes it across segments using macro-level trends and established proportions.
- Bottom-Up Approach – Aggregates company-level and country-level revenue data to build regional and global market estimates.
These two approaches are cross-validated to remove inconsistencies and ensure accurate market estimation.
Forecasting Models and Market Dynamics Analysis
- Time-Series Analysis – Models historical trends, seasonality, and demand cycles.
- Econometric and Judgmental Forecasting – Combines economic models with expert-driven adjustments.
- Delphi Method – Uses iterative expert input to generate balanced market forecasts.
Data Triangulation and Validation
- Multi-source cross-verification of all data points
- Use of quantitative and qualitative validation techniques
- Sample validation through expert and stakeholder feedback
Market Analysis and Sizing Estimation
- Detailed segmentation analysis
- Competitive landscape evaluation
- Revenue modeling using TAM, SAM, and SOM frameworks
Quality Assurance and Final Review
- Data accuracy and consistency checks
- Content, language, and structure review
- Client-specific customization and refinement
Continuous Improvement in Methodology
We continuously refine our research methodologies based on evolving market conditions, client feedback, and technological advancements. This ensures our research remains accurate, relevant, and aligned with industry standards.
Oligonucleotide CDMO Market Report Scope & Segmentation
| Attributes | Details |
|---|---|
| Market Size (Current)Current market valuation | US$ 1.88 Billion in 2026 |
| Market Size (Forecast)Projected market valuation | US$ 12.11 Billion in 2035 |
| Growth RateCompound Annual Growth Rate | CAGR of 23.0% from 2026 to 2035 |
| Forecast PeriodAnalysis timeline | 2026 – 2035 |
| Base YearReference year for analysis | 2025 |
| Historical Data AvailablePast market data availability | Yes |
| Regional ScopeGeographical coverage | Global |
| Segments CoveredMarket segments analyzed | By Service
By Type
By Application
By End Use
|
Leading companies covered in this report
- Agilent Technologies (U.S.)
- Bachem (Switzerland)
- WuXi AppTec (China)
- Thermo Fisher Scientific (U.S.)
- ST Pharm (South Korea)
- Lonza (Switzerland)
- Eurofins Scientific (Luxembourg)
- Ajinomoto (Japan)
- EUROAPI (France)
- PolyPeptide Group (Switzerland)
- BioSpring (Germany)
- Aurigene Pharmaceutical Services (India)
- Kaneka Corporation (Japan)
- Syngene International (India)
- and CordenPharma (Luxembourg)
Frequently Asked Questions
Common questions about this report
The study period covers historical insights and forecast projections for the period 2026-2035.
The global Oligonucleotide CDMO Market market is expected to grow at a CAGR of 23.0% during the forecast period 2026-2035.
The report offers comprehensive market segmentation analysis across key categories and sub-segments relevant to the industry, along with regional and competitive insights.
The market is projected to reach 12.11 Billion by 2035.
Key players in the Oligonucleotide CDMO Market include Agilent Technologies (U.S.), Bachem (Switzerland), WuXi AppTec (China), Thermo Fisher Scientific (U.S.), ST Pharm (South Korea), Lonza (Switzerland), Eurofins Scientific (Luxembourg), Ajinomoto (Japan), EUROAPI (France), PolyPeptide Group (Switzerland), BioSpring (Germany), Aurigene Pharmaceutical Services (India), Kaneka Corporation (Japan), Syngene International (India), and and CordenPharma (Luxembourg).
North America, Europe, and Asia Pacific are key regions covered in the report, including regional trends, market share, and growth opportunities.
Growing demand, technological advancements, changing consumer preferences, and increasing investments are some of the major factors supporting the growth of the Oligonucleotide CDMO Market market.
Yes, the report includes company profiling, competitive landscape analysis, strategic developments, mergers & acquisitions, product launches, and market positioning of leading industry participants.
The report is prepared using a combination of primary research, secondary research, expert interviews, industry databases, company annual reports, and proprietary market analysis models.
Yes, report customization options are available based on specific business objectives, geographic focus, competitive benchmarking requirements, and additional market segmentation needs.
Yes, the report is available in both PDF and Excel formats. The Excel file includes all market data tables, forecasts, and segment-wise data for easy analysis.
Yes, you can request a free sample report which includes an overview, table of contents, and sample data pages to help you evaluate the report before making a purchase decision.
About the Author
Market research expert with years of industry experience
As a Senior Research Associate at Econ Market Research, Akash Bhingare leads comprehensive market studies across dynamic and highly specialized sectors, ranging from advanced biotech fields to niche industrial markets. He excels at dissecting complex supply chains, analyzing market segmentation, and forecasting future industry trajectories. Akash’s commitment to high-fidelity data ensures that every report he authors delivers reliable, foundational knowledge for enterprise-level decision-making.










